BCM
TTPH

Bienville Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Bienville Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-325
Closed -$258K – 98
2014
Q4 		$258K Buy
+325
New +$175K 0.21% 72

Other funds holding TTPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bienville Capital Management's TTPH Position: Q1 2015 in Review

Bienville Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2015, closing a stake of 325 shares — an estimated $258K sold.

Bienville Capital Management first reported a position in TTPH in Q4 2014 and held it in 1 quarter. The position peaked at $258K in Q4 2014. 130 funds tracked by Wall St. Rank hold TTPH as of Q1 2015.

  • Bienville Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Bienville Capital Management sold 325 Tetraphase Pharmaceuticals, Inc. shares in Q1 2015, an estimated $258K.
  • Bienville Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • Bienville Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $258K in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2015.

Based on Bienville Capital Management's 13F filing for Q1 2015, filed 13 May 2015.